NYSE:PHGE

Biomx Stock Insider Trading

Healthcare > Biotechnology

Buy PHGE

*Your capital is at risk

$0.87

-0.0224 (-2.52%)

At Close: Jun 03, 2026

BiomX Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 8.43. In total, the insiders bought 42.14M and sold 5.92M PHGE shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	8.43
● Buy	42.14M shares
● Sell	5.92M shares
89% Buy Activity Weak Negative Correlation
Sell Signal Low Confidence Mar 17, 2026 Analysis Breakdown: Weakened by a contradictory positive Insider Power Score. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Apr 14, 2025 Buy	Common Stock Options - right to Buy A-Award	Blum Susan Director	Director	17 600 Value: $9K
Apr 14, 2025 Buy	Common Stock Options - right to Buy A-Award	Blum Susan Director	Director	17 600 Value: $9K
Apr 14, 2025 Buy	Common Stock A-Award	Solomon Jonathan Eitan Chief Executive Officer	CEO / President	126 748 Value: $1.34M
Apr 14, 2025 Buy	Common Stock Options - right to Buy A-Award	Solomon Jonathan Eitan Chief Executive Officer	CEO / President	380 500 Value: $204.7K
Apr 14, 2025 Buy	Common Stock Options - right to Buy A-Award	Moses Alan Charles Director	Director	17 600 Value: $9K
Apr 14, 2025 Buy	Common Stock Options - right to Buy A-Award	Williams Eddie Director	Director	17 600 Value: $9K
Apr 14, 2025 Buy	Common Stock A-Award	Bassan Merav Chief Development Officer	Officer	79 597 Value: $843.9K
Apr 14, 2025 Buy	Common Stock Options - right to Buy A-Award	Bassan Merav Chief Development Officer	Officer	95 000 Value: $51.1K
Apr 14, 2025 Buy	Common Stock Options - right to Buy A-Award	Goodman Jesse Director	Director	17 600 Value: $9K
Apr 14, 2025 Buy	Common Stock Options - right to Buy A-Award	Leff Jonathan S Director	Director	17 600 Value: $9K
Apr 14, 2025 Buy	Common Stock Options - right to Buy A-Award	Greig Russell Director	Director	35 200 Value: $18.9K
Apr 14, 2025 Buy	Common Stock A-Award	Wolfson Marina Chief Financial Officer	C-Suite Officer	68 545 Value: $726.7K
Apr 14, 2025 Buy	Common Stock Options - right to Buy A-Award	Wolfson Marina Chief Financial Officer	C-Suite Officer	95 000 Value: $51.1K
Apr 14, 2025 Buy	Stock Option (Right to Buy) A-Award	Flynn James E *director By Deputization	Director	17 600 Value: $9K
Feb 27, 2025 Buy	Warrants A-Award	Flynn James E *director By Deputization	Director	1 258 614 Value: $16.3M
Feb 27, 2025 Buy	Common Stock M-Exempt	Flynn James E *director By Deputization	Director	353 249 Value: $328.7K
Feb 27, 2025 Buy	Warrants M-Exempt	Flynn James E *director By Deputization	Director	1 611 863 Value: $20.8M
Feb 27, 2025 Buy	Warrants A-Award	Flynn James E *director By Deputization	Director	1 258 614 Value: $16.3M
Feb 27, 2025 Buy	Warrants M-Exempt	Flynn James E *director By Deputization	Director	1 611 863 Value: $20.8M
Feb 27, 2025 Buy	Common Stock M-Exempt	Flynn James E *director By Deputization	Director	353 249 Value: $328.7K
Feb 26, 2025 Buy	Common Stock J-Other	Cystic Fibrosis Foundation Insider	Other	0 Value: $0
Feb 26, 2025 Buy	Common Stock J-Other	Cystic Fibrosis Foundation Insider	Other	0 Value: $0
Sep 16, 2024 Buy	Common Stock A-Award	Bassan Merav Chief Development Officer	Officer	31 749 Value: $594.2K
Sep 16, 2024 Buy	Common Stock A-Award	Solomon Jonathan Eitan Chief Executive Officer	CEO / President	50 556 Value: $946.3K
Sep 16, 2024 Buy	Common Stock A-Award	Oron Assaf Chief Business Officer	Officer	25 804 Value: $483.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT BIOMX INC.

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for ...

Read Full Profile Here